Owkin · 公司檔案
Owkin · 法国/美国 · AI與模型數據
登記關注方向：多模态生物医学AI、联邦学习、药物发现。關注方向是目錄字段；具體能力請核查下方來源與項目證據。
公開已核驗進展
Owkin 与赛诺菲合作开发药物研发 AI 智能体
Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據
据 Owkin 官方公告，与赛诺菲开展多年合作，共同开发生物医药 AI 智能体，安排包含五年许可。该信息属于商业研发安排。
Owkin 与阿斯利康签订三年 K Pro 许可安排
Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據
据 Owkin 官方公告，与阿斯利康达成安排，基于三年 K Pro 许可开发生物医药 AI 智能体。不是已验证的临床效果。
合作、許可與並購時間線
Owkin 与赛诺菲合作开发药物研发 AI 智能体
Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據
据 Owkin 官方公告，与赛诺菲开展多年合作，共同开发生物医药 AI 智能体，安排包含五年许可。该信息属于商业研发安排。
Owkin 与阿斯利康签订三年 K Pro 许可安排
Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 1 條當前公開證據
据 Owkin 官方公告，与阿斯利康达成安排，基于三年 K Pro 许可开发生物医药 AI 智能体。不是已验证的临床效果。
以上來自最新 2 條已核驗進展。合作事件成立與模型效果、實驗結果或臨床進度分別需要證據。
公開原文線索
Estonia and Owkin Partner to Advance Sovereign AI in Biology
Owkin official newsroom · 行業原文收錄 · 來源發佈：Tue Sep 29 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:00 GMT+0000 (Coordinated Universal Time)
Tallinn / Paris, 29 September 2026 – Estonia, led by the National Applied Research Center Metrosert, and Owkin today announced a collaboration to advance sovereign AI in biological and health research, working with Metro
Owkin to License K Pro and Multimodal Data to Servier to Advance Oncology Research
Owkin official newsroom · 行業原文收錄 · 來源發佈：Fri Sep 11 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:48 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - September 11, 2026 — Owkin, the agentic AI company pioneering the first automated AI scientist to revolutionize drug discovery and development, today announced an agreement with Servier, an independent
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim
Owkin official newsroom · 行業原文收錄 · 來源發佈：Wed Sep 02 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:56 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together
Owkin and CRO Aviano Sign Master Partnership Agreement to Foster Collaborative Oncology Research
Owkin official newsroom · 行業原文收錄 · 來源發佈：Fri Aug 07 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:15 GMT+0000 (Coordinated Universal Time)
PARIS & PORDENONE, Italy — Owkin, the agentic AI company pioneering the first autonomous AI scientist to revolutionize drug discovery and development, and the Centro di Riferimento Oncologico di Aviano (CRO), a leading I
Owkin to Integrate Kognitic's Clinical Trial Data Into K Pro Through New Collaboration
Owkin official newsroom · 行業原文收錄 · 來源發佈：Thu Aug 06 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:09:24 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS — Owkin, the agentic AI company pioneering Biological Artificial SuperIntelligence to revolutionize drug discovery and development, today announced a data collaboration with Kognitic to integrate Kogniti
Owkin to Build AI Agents as Part of a Multi-Year K Pro Collaboration with Sanofi
Owkin official newsroom · 行業原文收錄 · 來源發佈：Fri Jun 05 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:10 GMT+0000 (Coordinated Universal Time)
NEW YORK & PARIS - 5th June, 2026 - Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to transform drug discovery and development, today announced a multi-year collaboration with Sanofi to
Owkin and BeOne Medicines Sign Clinical Supply Agreement for Tislelizumab in INVOKE Trial of OKN4395
Owkin official newsroom · 行業原文收錄 · 來源發佈：Mon Jun 01 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:24 GMT+0000 (Coordinated Universal Time)
BeOne Medicines will supply tislelizumab, its PD-1 inhibitor, to Owkin's ongoing INVOKE Phase 1a/1b trial of OKN4395 in patients with advanced solid tumors (NCT06789172). The agreement opens a combination arm pairing OKN
Owkin to Build AI Agents as Part of a Multi-Year K Pro License Agreement with AstraZeneca
Owkin official newsroom · 行業原文收錄 · 來源發佈：Wed May 13 2026 00:00:00 GMT+0000 (Coordinated Universal Time) · 本站收錄：Thu Oct 08 2026 09:08:37 GMT+0000 (Coordinated Universal Time)
Owkin, the agentic AI company pioneering Biological Artificial Superintelligence to revolutionize drug discovery and development, today announced an agreement with AstraZeneca to build biopharma agents as part of their t
已驗證的官方與訂閱來源
- Owkin official newsroom · 採集已啓用 · 最近成功 Fri Oct 09 2026 08:09:51 GMT+0000 (Coordinated Universal Time)
來源驗證與持續採集分別顯示；原文收錄不自動成為已核驗事件。
專題指南：從原文到判斷
按任務比較模型，按證據追蹤合作；每篇保留原始出處與更新日期。
虛擬細胞、AI 模型與公司：應該怎樣比較？
按輸入、輸出、任務和驗證條件比較單細胞模型、結構預測與蛋白設計，並區分模型論文與公司能力。
閱讀指南 · 更新 2026-10-08
AI 制藥公司合作時間線：從公告讀到證據
用真實官方公告區分合作主體、首付款、條件性里程碑和研發進度，並建立可追溯的合作時間線。
閱讀指南 · 更新 2026-10-08
每週 AI 制藥信息怎麼讀：公司動態、研究進展與覆蓋缺口
建立每週閱讀順序，分清公告、論文與臨床結果；理解本站本週收錄的時間窗口、分母和來源覆蓋。
閱讀指南 · 更新 2026-10-08